ISSN: 2755-1059

Journal of Nephrology & Endocrinology Research

SCIENTIFIC Research and Community

Research Article

Open Access

Palm-Derived Tocotrienols and the Postmenopausal Bone–Metabolism Axis: Source-Specific Evidence Linking Oxidative Stress, Lipid Remodelling, Estrogen Deficiency, and Skeletal Health

Loso Judijanto

IPOSS Jakarta, Indonesia

ABSTRACT

Postmenopausal osteoporosis is increasingly understood as an endocrine–metabolic skeletal disorder in which estrogen deficiency interacts with oxidative stress, inflammation, mitochondrial dysfunction, lipid remodelling, marrow adiposity, insulin resistance, and deterioration of bone–muscle communication. Tocotrienols, unsaturated vitamin-E isoforms occurring prominently in palm oil, have therefore attracted interest as potential nutritional modulators of pathways relevant to skeletal aging. This qualitative literature review critically evaluates the biological plausibility and translational evidence linking tocotrienols with postmenopausal bone health, emphasising the distinction between palm-derived tocotrienol-rich fractions and tocotrienol preparations from other botanical sources. Evidence indicates that tocotrienols can influence oxidative and inflammatory signaling, lipid metabolism, mevalonate-pathway activity, osteoblast–osteoclast coupling, and systemic metabolites. A randomized study in postmenopausal osteopenic women further demonstrated metabolomic alterations involving lysophospholipids, acylcarnitines, tryptophan-related metabolites, and steroid-associated pathways. However, human skeletal evidence remains limited by short intervention periods, reliance on biomarkers, and inadequate assessment of bone mineral density, microarchitecture, fractures, muscle function, and clinically relevant outcomes. Most importantly, positive findings obtained with δ/γ-dominant non-palm formulations cannot automatically be extrapolated to multi-isoform palm-derived products. Future research should prioritize formulation-specific randomized trials, pharmacokinetic characterization, DXA and advanced imaging, metabolomics, vitamin-D stratification, and combined bone–muscle endpoints.

***Corresponding author**

Loso Judijanto, IPOSS Jakarta, Indonesia.

Received: October 09, 2026; **Accepted:** October 14, 2026; **Published:** October 24, 2026

Keywords: Tocotrienol, Palm Oil, Postmenopausal Osteoporosis, Estrogen Deficiency, Oxidative Stress, Lipid Metabolism, Bone Remodeling, Metabolomics, Marrow Adiposity, Osteosarcopenia

JEL Classification: I10; I12; I18; Q13; Q16

Introduction

Postmenopausal osteoporosis is conventionally described as a disorder of accelerated bone loss following estrogen withdrawal, but that description is increasingly insufficient. Estrogen deficiency does initiate a major shift in skeletal remodeling by favoring osteoclast formation and activity, weakening anti-resorptive signaling and altering osteoblast and osteocyte function. Yet the resulting loss of bone strength emerges from a broader network that includes oxidative stress, inflammatory signaling, mitochondrial dysfunction, dysregulated lipid metabolism, changes in bone-marrow adiposity, insulin resistance, and deterioration of muscle–bone communication. Contemporary understanding therefore places postmenopausal osteoporosis within an integrated endocrine–metabolic context rather than regarding the skeleton as an isolated mineral reservoir [1-3].

The consequences of estrogen withdrawal are particularly important because bone is a dynamic tissue whose mechanical competence depends not only on Bone Mineral Density (BMD) but also on cortical structure, trabecular organization, material properties, and the balance between resorption and formation. RANKL-RANK signaling is central to osteoclast differentiation, whereas osteoprotegerin acts as a decoy receptor that restrains this pathway. Estrogen deficiency modifies this regulatory environment while also affecting Wnt-related osteoblast signaling and the cellular interactions that coordinate the remodeling unit. These pathways provide a mechanistic framework for understanding why changes in circulating hormones, inflammatory mediators, and oxidative status can rapidly influence skeletal turnover [2-5].

A second conceptual shift concerns redox biology. Reactive oxygen species are no longer viewed simply as nonspecific by-products of aging. When produced in excess or insufficiently neutralized, they can promote osteoclastogenesis, impair osteoblast differentiation, damage mitochondrial function, and interact with pro-inflammatory pathways. Meta-analytic evidence in postmenopausal women indicates associations between osteoporosis and altered oxidative-stress biomarkers, while mechanistic literature increasingly emphasizes Nrf2-dependent antioxidant defenses and lipid-peroxidation pathways as relevant components of skeletal homeostasis [6-8].

These observations provide a rationale for investigating nutritional compounds capable of influencing several nodes in the bone–

metabolism network simultaneously. Tocotrienols are members of the vitamin-E family characterized by an unsaturated isoprenoid side chain and occurring as α-, β-, γ-, and δ-isoforms. Experimental and clinical evidence has associated tocotrienols with antioxidant activity, modulation of inflammatory signaling, effects on lipid metabolism and possible regulation of the mevalonate pathway. Their relevance to the palm-oil sector is especially important because palm oil is a major commercial source of Tocotrienol-Rich Fractions (TRF), which typically contain multiple tocotrienol isoforms together with tocopherol components [9-11].

However, "tocotrienol" is not a sufficiently precise intervention label for translational interpretation. Tocotrienol preparations differ in botanical source, isoform distribution, tocopherol co-content, dose, delivery system, and systemic exposure. This problem is particularly relevant to osteoporosis research because some influential postmenopausal studies used annatto-derived preparations enriched predominantly in δ- and γ-tocotrienols, whereas palm TRF is compositionally different. Pharmacokinetic reviews further demonstrate that formulation and food conditions influence tocotrienol absorption and bioavailability, making source and delivery characteristics potential determinants of biological response [12-14].

This distinction creates the central research problem addressed in the present qualitative literature review. Positive skeletal or metabolic findings from an annatto δ/γ-tocotrienol formulation cannot automatically be interpreted as evidence that a palm-derived multi-isoform TRF will produce the same magnitude or pattern of effect. The recent systematic review of randomized controlled trials involving palm TRF demonstrates a growing human evidence base across inflammatory, metabolic, and other outcomes, but does not establish equivalent long-term evidence for postmenopausal fracture prevention or preservation of skeletal microarchitecture [15].

Accordingly, this review has five interrelated aims. First, it examines the biological links among estrogen deficiency, oxidative stress, inflammation, mitochondria, lipid metabolism, and skeletal remodeling. Second, it evaluates how tocotrienols could theoretically intersect with these pathways. Third, it analyzes human and translational evidence with particular attention to metabolomic findings. Fourth, it integrates bone with marrow adipose tissue, insulin resistance, and the muscle–bone axis. Finally, it critically evaluates source and isoform extrapolation and proposes a research roadmap specifically for palm-derived tocotrienol formulations.

Literature Review: Conceptual and Theoretical Foundations

Estrogen Deficiency and Remodeling Imbalance

Bone remodeling depends on coordinated activity among osteoclasts, osteoblasts, and osteocytes. Osteoclasts resorb old or damaged bone, whereas osteoblast lineage cells replace the resorbed matrix and regulate mineralization. Osteocytes serve as mechanosensory and endocrine-like regulators that influence both formation and resorption. Estrogen participates in this system by reducing pro-osteoclastic signals, supporting osteoblast and osteocyte survival, and restraining excessive inflammatory activation. Consequently, estrogen withdrawal after menopause uncouples remodeling toward disproportionately high resorption, particularly during the early postmenopausal period [2-17].

RANKL-RANK-OPG signaling provides one of the clearest molecular explanations for this shift. RANKL expressed by osteoblast-lineage cells and other cells binds RANK on osteoclast precursors and promotes their maturation. OPG competes for RANKL and therefore restrains osteoclastogenesis. The clinical importance of this pathway is demonstrated by the effectiveness of RANKL inhibition in osteoporosis, but its relevance extends beyond pharmacotherapy because inflammatory cytokines, endocrine factors, and oxidative signals can all modify the osteoclastogenic environment [4]. Estrogen deficiency is therefore better interpreted as a regulatory perturbation that changes the responsiveness of a wider cellular network rather than as a single linear cause of bone loss.

Wnt/β-catenin signaling is complementary to the RANKL axis because it regulates osteoblast differentiation, bone formation, and cellular lineage allocation. Wnt signaling is controlled by multiple agonists and antagonists, including sclerostin and DKK-related proteins. Disturbances in Wnt-related pathways can impair bone formation even when bone resorption is not dramatically elevated. This point is important for a tocotrienol-centered review because a useful nutritional intervention would ideally preserve both sides of the remodeling equation rather than merely suppress a single osteoclast signa [5].

Oxidative Stress, Inflammation and Osteoimmunology

The relationship between estrogen deficiency and oxidative stress is biologically plausible because estrogen has antioxidant and anti-inflammatory functions in several tissues. Following menopause, an unfavorable redox environment can emerge through increased reactive oxygen species generation, reduced antioxidant capacity and dysregulated mitochondrial function. These changes can stimulate osteoclast differentiation while compromising osteoblast survival and matrix synthesis. Importantly, oxidative stress and inflammation reinforce each other: ROS can activate inflammatory transcriptional programs, whereas inflammatory cytokines can increase oxidant production and further intensify tissue damage [1-6].

The inflammatory component of postmenopausal bone loss includes signaling through TNF-α, IL-1β, IL-6 and NF-κB-related pathways. These mediators can promote osteoclastogenesis directly or indirectly, increase sensitivity to RANKL and interfere with osteoblastogenesis. This is the basis of the osteoimmunology concept: bone cells and immune cells share signaling molecules, cellular precursors and cytokine networks. Chronic low-grade inflammation in aging therefore creates a systemic context in which endocrine and metabolic disturbances can be translated into accelerated skeletal turnover.

Nrf2 is especially relevant because it coordinates expression of endogenous antioxidant enzymes and supports cellular defense against electrophilic and oxidative injury. Recent reviews describe Nrf2 as a regulator of both osteoblast and osteoclast biology, although its effects are context- and intensity-dependent rather than uniformly anabolic. The translational implication is that a nutritional antioxidant should not be evaluated solely by its ability to lower a circulating oxidation marker; meaningful skeletal action would require restoration of a cellular redox environment compatible with balanced remodeling [8].

Tocotrienols fit this conceptual framework because vitamin-E compounds can interact with lipid radicals and membrane oxidative processes. Nevertheless, the clinical literature does not support a simplistic claim that tocotrienol supplementation uniformly reduces all inflammatory and oxidative biomarkers

[7]. found heterogeneity across randomized trials, reinforcing the need to consider dose, isoform composition, baseline metabolic condition, and outcome selection. This uncertainty is valuable rather than inconvenient: it argues for mechanism-informed trials instead of assuming that antioxidant capacity in vitro guarantees skeletal efficacy in vivo.

Mitochondrial Dysfunction, Lipid Peroxidation and Ferroptotic Biology

Mitochondria are central to skeletal-cell energetics and signaling. Osteoblast differentiation and matrix production require substantial energy, while osteoclast function also depends on coordinated mitochondrial adaptation. Aging, estrogen deficiency, and metabolic disease may reduce mitochondrial quality, alter fission–fusion dynamics, disturb mitophagy, and increase mitochondrial ROS. Recent reviews therefore position mitochondrial dysfunction as a potentially important mechanism linking systemic aging to disturbed bone remodeling [18].

Lipid peroxidation adds another layer to this mechanism. Oxidative damage to polyunsaturated membrane lipids can disrupt organelle function and participate in ferroptosis, an iron-dependent form of regulated cell death. Ferroptosis has attracted attention in osteoporosis because osteoblasts, osteocytes and osteoclast-lineage cells can be affected by iron handling, glutathione status, lipid-peroxide accumulation and related regulatory systems. Reviews published since 2023 have linked iron accumulation, lipid oxidation and ferroptotic signaling with skeletal deterioration, although the field remains predominantly mechanistic and preclinical [19-20].

This area is relevant to tocotrienols because their lipophilic structure places them within biological membranes and lipoprotein environments where lipid oxidation occurs. A plausible skeletal mechanism would therefore include preservation of membrane redox integrity and mitochondrial function. However, evidence that a particular palm-derived formulation prevents osteoblast ferroptosis or improves mitochondrial performance in postmenopausal women remains insufficient. The pathway should be presented as a hypothesis-generating bridge between tocotrienol biology and osteoporosis, not as an established clinical mechanism.

Lipid Metabolism, Marrow Adiposity and the Skeleton

Bone and lipid metabolism intersect at multiple biological levels. Mesenchymal stromal cells can differentiate toward osteogenic or adipogenic lineages, making lineage allocation a potential determinant of skeletal aging. Bone marrow adipose tissue is also metabolically active: it releases fatty acids, adipokines, and cytokines and participates in communication with hematopoietic and skeletal cells. Estrogen deficiency can favor marrow-adipose expansion, while higher marrow fat has been associated with lower bone mass in postmenopausal populations [21-23]. More recent physiological synthesis emphasizes that bone marrow adipose tissue is a dynamic signaling and energy-storage compartment whose relationship with bone is context dependent rather than uniformly inverse [24].

The emerging concept of bone marrow adipose tissue as an endocrine and metabolic organ has important implications for osteoporosis. Adipocytes and osteoblasts share mesenchymal progenitors, and signals that favor PPARγ-related adipogenesis can reduce osteogenic allocation. Meanwhile, marrow adipocytes may influence bone through adiponectin, leptin, inflammatory mediators, and local fuel provision [25]. emphasized the relevance of marrow adipose tissue to postmenopausal osteoporosis, while [26]. highlighted the responsiveness of this compartment to nutrition and weight change.

Adipokine research supports this framework but also demonstrates complexity. Meta-analytic evidence indicates that common circulating adipokines are associated with postmenopausal osteoporosis, although effect estimates vary across markers and study populations, while newer reviews describe additional adipokines capable of influencing osteoblast and osteoclast biology. Such evidence cautions against interpreting adiposity merely as mechanical loading that protects the skeleton, because adipose tissue can simultaneously exert inflammatory, endocrine, and metabolic effects that may compromise bone quality [27-29].

Mechanosensitive marrow-lipid biology further illustrates the dynamic nature of this compartment [30]. demonstrated that mechanical stimulation can mobilize marrow fat to support osteogenesis and lymphopoiesis through a local signaling network. Although these findings are not direct evidence for tocotrienols, they establish that lipid flux within bone marrow is biologically meaningful and responsive to systemic and mechanical cues. This makes lipidomics and marrow-fat measures rational exploratory outcomes in future tocotrienol trials.

Circulating Lipids, Metabolic Syndrome and Insulin Resistance

Epidemiological relations between circulating lipids and bone are inconsistent, but inconsistency itself is informative because lipid concentrations are influenced by diet, adiposity, medication, insulin sensitivity, genetics and menopause [31]. for example, reported positive associations between HDL cholesterol and BMD at selected sites in postmenopausal women, whereas more recent pooled analyses have identified different patterns involving triglycerides and HDL [32]. reported that serum lipid profiles differed between women with normal bone mass, osteopenia, and osteoporosis, but the observational design prevents simple causal interpretation [31-32].

Metabolic syndrome adds further complexity [33]. found that associations between metabolic syndrome and osteoporosis vary across populations and components, illustrating the need to distinguish central obesity, blood pressure, dysglycemia, and dyslipidemia rather than treating metabolic syndrome as a uniform exposure. In clinical practice, postmenopausal osteoporosis frequently coexists with obesity, diabetes, dyslipidemia and cardiovascular disease, creating medication interactions and competing risks that influence treatment strategy [3-33].

Type 2 diabetes is especially important because fracture risk can be elevated despite relatively preserved or higher BMD [34]. reviewed evidence showing that conventional BMD-derived T-scores do not fully capture diabetic skeletal fragility. Hyperglycemia, advanced glycation, impaired bone material properties, falls risk, microvascular disease, and altered turnover may all contribute. Thus, metabolic phenotype should be considered when designing tocotrienol trials: an intervention that improves a metabolic biomarker might have different skeletal implications in a metabolically healthy postmenopausal woman than in a woman with long-standing diabetes.

Insulin resistance itself may be associated with BMD and body-composition variables, although directionality and confounding remain difficult to resolve [35]. recently examined surrogate indices of insulin resistance in non-diabetic postmenopausal women, reinforcing the rationale for metabolic stratification in skeletal research. Future trials of palm TRF should therefore measure

fasting glucose, insulin, lipid profiles, and body composition rather than limiting phenotyping to age and baseline T-score.

Tocotrienol Biology and the Importance of Botanical Source

Tocotrienols differ from tocopherols by the presence of an unsaturated side chain, which influences membrane distribution, metabolism, and biological behavior. α-, β-, γ-, and δ-tocotrienols differ in methyl substitution patterns and may not have identical potency across pathways. Reviews of tocotrienol biology describe antioxidant, anti-inflammatory, neuroprotective, metabolic, and skeletal actions, while meta-analytic evidence suggests that effects on lipid profiles are not uniformly consistent across trials and contemporary bone-focused reviews still characterize the human skeletal evidence as limited [9-38].

Palm oil is a particularly important commercial source because palm-derived TRF naturally provides a mixture of tocotrienol isoforms together with α-tocopherol. In contrast, annatto-derived preparations are commonly dominated by δ- and γ-tocotrienols and may contain little or no α-tocopherol. This compositional distinction may alter absorption, tissue exposure and pathway-level effects [10]. reviewed palm-oil vitamin-E-derived tocotrienols in inflammatory and chronic-disease contexts, while [11-15] systematically evaluated randomized trials specifically involving palm TRF. These studies strengthen the evidence base for palm-derived preparations but also show that their human clinical literature spans diverse endpoints rather than providing definitive postmenopausal skeletal outcome data.

Pharmacokinetics make this source distinction more important. Tocotrienol absorption is influenced by food intake, formulation technology, dose, and competition within vitamin-E transport systems. Human pharmacokinetic evidence shows substantial variability across preparations, and recent formulation research highlights poor and variable oral bioavailability as a continuing translational constraint. Consequently, a trial using a high-bioavailability δ-tocotrienol-rich annatto preparation is not biologically equivalent to a trial using a conventional palm TRF mixture at the same nominal milligram dose [12-39].

Figure 1 integrates the principal biological pathways through which estrogen deficiency can propagate skeletal deterioration. The framework places oxidative stress, inflammatory signaling, mitochondrial dysfunction, lipid remodeling, marrow adiposity, and insulin resistance between the endocrine trigger and the final structural outcomes of bone loss and fragility.




Figure 1: The Postmenopausal Bone-Metabolism Axis

Figure 1 depicts estrogen deficiency as the initiating endocrine disturbance and traces its connections to increased RANKL signaling, reduced osteoblast support, oxidative stress, inflammatory cytokines, mitochondrial dysfunction, altered lipid metabolism, and marrow adiposity. These pathways converge on increased osteoclastogenesis, impaired osteoblastogenesis, bone-muscle deterioration, lower BMD, microarchitectural decline, falls, and greater fracture susceptibility.

The significance of Figure 1 is that no single pathway fully explains postmenopausal bone deterioration. Estrogen withdrawal is the initiating endocrine disturbance, but its skeletal consequences are magnified by redox, inflammatory and metabolic processes that also occur in obesity, insulin resistance and aging. This integrated view provides the biological rationale for studying tocotrienols as pathway modulators while simultaneously showing why antioxidant activity alone would be an inadequate basis for a therapeutic claim.

Method

This study was designed as a Qualitative Literature Review (QLR), not a systematic literature review or meta-analysis. The objective was interpretive and thematic: to integrate mechanistic, translational and clinical evidence concerning postmenopausal bone loss and tocotrienol biology, with explicit attention to botanical source and isoform composition. The review therefore did not use PRISMA

reporting, exhaustive study enumeration, pooled effect estimates or formal risk-of-bias scoring as requirements for inclusion.

Literature identification emphasized articles published from January 2020 through October 2026 in PubMed/MEDLINE, Scopus, Web of Science, ScienceDirect and Google Scholar. Search concepts included combinations of tocotrienol, palm tocotrienol-rich fraction, palm vitamin E, annatto tocotrienol, postmenopausal osteoporosis, estrogen deficiency, oxidative stress, RANKL, osteoclast, osteoblast, Nrf2, lipid metabolism, bone marrow adipose tissue, insulin resistance, metabolomics, lysophospholipid, acylcarnitine, sarcopenia and osteosarcopenia. Preference was given to peer-reviewed randomized trials, systematic reviews, meta-analyses, human observational studies and contemporary mechanistic reviews from reputable journals.

The analytical procedure involved iterative thematic coding rather than quantitative evidence pooling. Studies were grouped into six interacting domains: estrogen-dependent bone remodeling; oxidative and inflammatory mechanisms; mitochondrial and ferroptotic mechanisms; lipid and marrow-adipose metabolism; systemic metabolic and muscle–bone interactions; and tocotrienol source/formulation effects. Tocotrienol studies received additional classification according to botanical source, isoform profile, tocopherol co-content, total dose, delivery system, intervention duration and outcome category.

This source-specific extraction strategy was necessary because intervention labels in the literature are frequently insufficiently precise. A study described simply as "tocotrienol supplementation" was not treated as direct evidence for palm-derived TRF unless the formulation source and composition were clearly reported. This approach also distinguishes mechanistic plausibility from formulation-specific clinical efficacy, which is the central methodological principle of the present review.

The evidence was interpreted through triangulation. Human randomized trials were given greatest translational weight, but biomarker findings were evaluated alongside preclinical data to determine whether proposed mechanisms were biologically coherent. Observational associations were used to characterize the metabolic context of postmenopausal bone loss but were not interpreted as proof of causality. Guidelines and clinical reviews were used to frame established osteoporosis management and to prevent nutritional supplementation from being positioned as a replacement for proven fracture-prevention strategies [16-17].

Results: Thematic Findings

Tocotrienols and Bone Turnover: A Plausible but Incompletely Proven Relationship

Recent reviews of tocotrienols and musculoskeletal aging consistently identify antioxidant, anti-inflammatory, anti-resorptive, and mevalonate-related mechanisms that could be relevant to osteoporosis [13]. synthesized evidence related specifically to perimenopausal-associated osteoporosis, while [14]. extended the discussion to age-related musculoskeletal disorders and [38]. updated the skeletal evidence base [40]. similarly summarized mechanisms relevant to glucocorticoid-induced osteoporosis, demonstrating that the skeletal interest in tocotrienols is not limited to estrogen deficiency. Collectively, these reviews support biological plausibility but also show that much of the mechanistic evidence remains preclinical and that human skeletal trials remain scarce [13-40].

Animal work is relevant because it allows direct assessment of bone histomorphometry and microarchitecture under controlled conditions [41]. for example, investigated annatto tocotrienol delivered using a self-emulsifying system in an ovariectomy-related model of postmenopausal bone loss. Such studies indicate that delivery technology and bioavailability may alter skeletal response, but they also reinforce the need to avoid assuming that a formulation optimized in an animal model will produce clinically meaningful fracture prevention in humans.

The strongest human evidence remains limited in duration and endpoint scope. Biomarker changes can indicate altered remodeling, but bone-turnover markers respond much faster than BMD, microarchitecture or fracture incidence [42]. highlighted the potential value and limitations of biomarkers in pharmacological osteoporosis monitoring. The same caution applies even more strongly to nutraceutical trials: a short-term reduction in a resorption marker should be interpreted as evidence of biological activity, not as a surrogate demonstration that fractures will be prevented.

Metabolomic Evidence Suggests Systemic Remodeling Beyond Antioxidant Scavenging

One of the most informative recent findings comes from the randomized metabolomics analysis reported by [43]. In postmenopausal osteopenic women, tocotrienol supplementation was associated with changes across multiple circulating metabolite classes, including higher levels of selected lysophospholipids and lower acylcarnitines, together with alterations in tryptophan- and steroid-related metabolism. These results broaden the interpretation of tocotrienol action from direct radical scavenging toward systemic metabolic remodeling [43].

The lysophospholipid signal is potentially relevant to cell membranes, inflammatory signaling and lipid transport. Changes in acylcarnitines are particularly interesting because acylcarnitines are linked to mitochondrial fatty-acid handling and can reflect incomplete β-oxidation or altered metabolic flux. However, metabolomic signatures are associative fingerprints rather than proof that a specific pathway mediates improved skeletal outcomes. The correct interpretation is therefore that tocotrienol supplementation generated measurable systemic metabolic effects that deserve mechanistic follow-up.

The tryptophan-related findings also connect with an emerging gut–bone literature [44]. reported differences in gut microbial and serum metabolic profiles among postmenopausal women with reduced BMD, including pathways related to tryptophan metabolism [45]. subsequently demonstrated in an ovariectomized model that microbial tryptophan metabolites could influence bone loss through intestinal AhR-related signaling, barrier function and immune pathways. These studies do not establish that tocotrienols act through the gut–bone axis, but they make tryptophan-metabolite changes after supplementation biologically noteworthy rather than incidental [44-45].

The integration of these findings is presented in Figure 2, which moves beyond the traditional model of tocotrienols as membrane antioxidants. The figure identifies several plausible intervention nodes while distinguishing pathways supported mainly by mechanistic data from those supported by human metabolic observations.




Figure 2: Potential Multi-Pathway Actions of Tocotrienols in Postmenopausal Skeletal Metabolism

Figure 2 emphasizes the distinction between possible mechanisms and demonstrated clinical endpoints. The network is biologically coherent because redox biology, lipid metabolism, and osteoclast signaling interact, but the current evidence does not justify assigning equal certainty to every pathway. This visual hierarchy should prevent mechanistic enthusiasm from being misrepresented as clinical proof.

Lipid and Inflammatory Effects Are Relevant but Formulation-Dependent

Tocotrienols have been investigated extensively in cardiometabolic settings, which provides indirect information relevant to the bone–metabolism axis [37]. analyzed randomized trials of tocotrienol supplementation and reported lipid-profile effects that differed by lipid fraction and intervention characteristics. More broadly, [10]. reviewed palm-derived tocotrienols in inflammation and chronic disease, while [7]. found inconsistent effects across inflammatory and oxidative-stress biomarkers. These findings show that tocotrienol biological activity is measurable but not uniform across preparations and populations [7-37].

Evidence from metabolic-disease trials is also relevant because many postmenopausal women at fracture risk have diabetes or dyslipidemia [46]. compared δ-tocotrienol with α-tocopherol in patients with fatty liver disease and evaluated hepatic and inflammatory outcomes. Although not a skeletal study, such research demonstrates that individual vitamin-E isoforms can have distinguishable metabolic effects. It therefore supports the article's central methodological argument: formulation composition should be treated as an active biological variable, not merely as product-description information.

A recent systematic review and meta-analysis of randomized trials in type 2 diabetes reported a modest reduction in HbA1c with TRF supplementation at 250-400 mg/day, while blood pressure and high-sensitivity C-reactive protein were not significantly reduced overall. This selective pattern again argues against treating tocotrienols as universally effective metabolic antioxidants and supports phenotype- and endpoint-specific interpretation. In the skeletal context, baseline diabetes, insulin resistance, and inflammatory status may determine whether a metabolic change is relevant to bone [47].

The Palm-versus-Annatto Extrapolation Problem Is a Major Evidence Gap

The most important thematic finding of this review is that the tocotrienol literature contains a persistent source-classification problem. Annatto-derived products are typically enriched in δ- and γ-tocotrienols, whereas palm TRF contains a broader mixture of tocotrienol isoforms and usually includes α-tocopherol. Because isoforms may differ in biological activity and pharmacokinetics, source-specific data cannot be assumed to be interchangeable [12]. showed substantial variation in tocotrienol pharmacokinetics across human studies, and formulation-based delivery strategies have been developed specifically to overcome limited and variable oral bioavailability.

This issue is directly relevant to the human postmenopausal evidence. The metabolomics trial by [43]. derived from a tocotrienol intervention in osteopenic women should be interpreted according to the actual formulation used, not retroactively generalized to palm TRF. Conversely, evidence from palm TRF trials in other clinical populations cannot establish postmenopausal skeletal efficacy simply because the ingredient belongs to the same vitamin-E family. The correct evidentiary unit is therefore source × isoform profile × formulation × dose × bioavailability × population × outcome [11]. provide the clearest recent synthesis specifically for palm-derived TRF. Their review identified 30 randomized trials involving 2,646 participants across several health conditions and suggested benefits in areas including inflammation and lipid peroxidation, while simultaneously emphasizing the need for additional

research on optimal dose, formulation, and duration. The review does not provide evidence equivalent to a long-duration fracture or BMD trial in postmenopausal osteoporosis, which is precisely why source-specific skeletal research remains necessary.

The source-specific evidence problem is summarized in Figure 3. This figure should be positioned prominently because it represents the principal methodological contribution of the review rather than a peripheral limitation.




Figure 3: Why Tocotrienol Source Matters: Palm-Derived Trf Versus Annatto-Dominant Preparations

Figure 3 prevents an important category error. A positive result obtained with one tocotrienol preparation provides evidence for that preparation and can inform mechanistic hypotheses about other formulations, but it does not demonstrate therapeutic equivalence. This distinction is particularly important for palm-sector research, where commercial relevance could otherwise encourage overgeneralization from non-palm interventions.

Bone–Muscle Crosstalk Extends the Relevant Outcome Space

Osteoporosis does not occur independently of age-related changes in skeletal muscle. The coexistence of osteoporosis and sarcopenia, often described as osteosarcopenia, increases the clinical relevance of falls, functional decline, and fractures [48]. emphasized the overlapping epidemiology and pathogenesis of these conditions, while [49]. described mechanical and biochemical communication between bone and muscle through myokines, osteokines, and age-related signaling networks [48-49].

More recent work has strengthened this concept [50]. reviewed muscle–bone crosstalk in osteosarcopenia, [51] discussed myokines and osteokines as mediators of inter-tissue communication, and [52] highlighted the potential role of RANKL signaling in bidirectional bone–muscle interactions. These findings suggest that interventions influencing RANKL, inflammation, or systemic metabolism could theoretically affect muscle as well as bone, although such cross-tissue effects need direct testing [50-52].

This broader perspective is especially relevant to nutritional research because supplement trials can readily incorporate muscle outcomes without displacing skeletal outcomes. Grip strength, gait speed, chair-rise performance, appendicular lean mass, and falls could be assessed together with BMD and bone turnover. Vitamin-D research provides a precedent [53] found evidence that vitamin-D supplementation can influence handgrip strength in postmenopausal women, illustrating how nutrient trials can meaningfully bridge bone and muscle outcomes.

Discussion and Analysis

Reframing Postmenopausal Osteoporosis as an Endocrine–Redox–Metabolic Disorder

The principal synthesis emerging from this literature is that estrogen deficiency should be viewed as an upstream trigger operating within a metabolically active organism. The skeleton responds not only to estrogen receptors but also to cytokines, redox state, mitochondrial energetics, lipid substrates, insulin signaling, mechanical loading, and secretory signals from adipose tissue and muscle. This explains why two postmenopausal women with similar BMD can have different rates of bone loss or fracture risk depending on diabetes, falls, body composition, inflammatory burden, and bone quality.

This integrated interpretation is consistent with clinical evidence showing that BMD alone does not capture all dimensions of skeletal fragility. Diabetes is a particularly clear example because fracture risk may remain elevated despite apparently favorable BMD measurements [34]. Trabecular bone score and other imaging or structural measures have therefore been explored as complements to BMD in selected clinical contexts [54]. Future nutraceutical trials should reflect this complexity by avoiding overreliance on a single surrogate outcome.

The same logic applies to nutritional background. Calcium and vitamin D remain foundational considerations, but supplementation effects depend on baseline status and clinical context. Meta-analysis by [55]. suggested benefits of combined calcium and vitamin D for selected BMD outcomes in postmenopausal women, while broader umbrella evidence indicates that fracture effects of vitamin-D supplementation are not universally positive across populations and trial designs [55-56]. A tocotrienol trial that ignores vitamin-D status and calcium intake would therefore risk attributing differences to tocotrienols that may actually reflect background nutritional heterogeneity.

Where Tocotrienols Fit Mechanistically

The strongest mechanistic argument for tocotrienols is not that they are "antioxidants for bone," but that they may interact with a network of redox, inflammatory, and metabolic pathways that influence remodeling. Antioxidant activity could reduce lipid oxidation and protect cellular membranes; modulation of inflammatory pathways could alter osteoclastogenic signaling; effects on the mevalonate pathway could influence osteoclast function; and changes in lipid metabolism could alter systemic or marrow-level metabolic environments. These effects are conceptually compatible with postmenopausal bone biology but differ in evidentiary maturity [13-40].

The mevalonate pathway deserves particular attention because inhibition of downstream prenylation processes is an established way to influence osteoclast biology pharmacologically. Tocotrienols have been discussed as modulators of HMG-CoA reductase and related lipid pathways, but contemporary reviews emphasize that the concentrations and tissue exposures required to generate clinically meaningful skeletal effects remain uncertain. This uncertainty again connects mechanism with pharmacokinetics: a nominal oral dose is less informative than actual systemic exposure to individual isoforms [9-38].

Mitochondrial biology provides another promising but incomplete bridge. Lower circulating acylcarnitines after tocotrienol supplementation could be compatible with altered fatty-acid flux or mitochondrial metabolism, but such a signal cannot specify whether osteoblast mitochondria, skeletal muscle, liver, or other tissues drove the change. Future trials should therefore combine untargeted metabolomics with targeted acylcarnitine panels, mitochondrial function markers and tissue-relevant phenotypes where feasible [18-43].

Metabolomics as a Bridge from Mechanism to Translational Phenotyping

Metabolomics is particularly valuable for this research agenda because osteoporosis is not simply a mineral-deficiency state. A systematic review of metabolomic studies of low BMD identified recurring signals across amino-acid, lipid, and carbohydrate metabolism but also substantial heterogeneity in populations, samples, and analytical platforms. The important methodological implication is that a metabolomic profile can reveal whether a nutritional intervention is producing systemic biological change even before structural bone outcomes become detectable, while longitudinal validation remains necessary [57].

The tocotrienol metabolomics trial provides a proof of concept. Altered lysophospholipids and acylcarnitines indicate that supplementation affected lipid-related metabolic networks, while changes in tryptophan and steroid-related metabolites create plausible connections to endocrine and gut-derived signaling. However, the next generation of studies should prospectively relate metabolite changes to P1NP, CTX, BMD, trabecular bone score, or HR-pQCT measures instead of analyzing metabolomics as a parallel outcome with uncertain skeletal meaning.

A longitudinal design would be particularly powerful. Early metabolite changes at 4–12 weeks could be modeled as predictors of later BMD or microarchitectural responses at 12–24 months. This would help determine whether metabolomic signatures are merely markers of exposure or mechanistic intermediates. It would also allow researchers to test whether palm TRF and annatto formulations generate distinct metabolic fingerprints even when total tocotrienol dose appears similar.

Why Palm-Specific Trials Are Necessary

Palm-derived TRF deserves direct testing because formulation-specific uncertainty is currently too large for reliable extrapolation. The case for such trials is strengthened, not weakened, by positive findings from annatto research. Those studies demonstrate that tocotrienol biology can be clinically measurable in postmenopausal women; they do not establish that all tocotrienol mixtures are equivalent.

A head-to-head trial would therefore be more informative than another placebo-controlled study of an unspecified tocotrienol supplement. A scientifically strong design could include a well-characterized palm TRF arm, a δ/γ-dominant annatto arm and a placebo arm, with equalization based on total tocotrienol dose and careful measurement of plasma isoform exposure. This would allow investigators to determine whether formulation differences alter metabolomic response, oxidative biomarkers, bone turnover, or longer-term skeletal outcomes.

Bioavailability should be treated as a trial endpoint rather than merely a formulation detail [12]. showed substantial pharmacokinetic variability among human tocotrienol studies, while more recent formulation research identifies low aqueous solubility, rapid elimination, chemical instability, and saturable intestinal absorption as barriers to consistent exposure. A null skeletal result in a poorly absorbed formulation could therefore reflect inadequate exposure rather than absence of biological potential, whereas a high-exposure formulation could alter safety, metabolic effects, or isoform interactions [39].

Integrating Obesity, Diabetes and Marrow Fat into Trial Design

The relationship between obesity and osteoporosis is not adequately described by the older assumption that higher body weight protects bone through loading [58]. found that obesity and fracture associations in postmenopausal women vary by fracture site, and broader meta-analytic evidence indicates that general and central obesity may have different relationships with osteoporosis. This heterogeneity likely reflects competing mechanical and metabolic effect [58].

For tocotrienol trials, obesity should therefore be measured as a phenotype rather than treated as a nuisance covariate. DXA-derived fat mass, visceral adiposity measures where available, waist circumference, and metabolic biomarkers could identify subgroups with different responses. Marrow adiposity is even more mechanistically relevant because it sits within the skeletal microenvironment. MRI- or spectroscopy-based marrow-fat assessment would be ambitious but highly informative in a mechanistic sub study [22-25].

Diabetes and insulin resistance also require deliberate handling. Because type 2 diabetes can increase fracture risk despite higher BMD, trials enrolling substantial numbers of diabetic participants should include stratified analyses rather than relying on BMD alone. Glycemic measures, diabetes duration, medications, and microvascular complications may all modify skeletal outcome [34]. Insulin-resistance indices could also be useful exploratory modifiers in women without diagnosed diabetes [35].

Clinical Positioning: Adjunctive Research, Not Therapeutic Substitution

Tocotrienols should not currently be positioned as replacements for established osteoporosis prevention or pharmacotherapy. Contemporary guidelines recommend fracture-risk assessment,

adequate calcium and vitamin D status, lifestyle measures, and evidence-based anti-osteoporotic medications according to clinical risk [16-17]. Nutritional compounds can be investigated as adjuncts, particularly where they plausibly influence metabolic pathways not fully addressed by conventional therapy, but such investigation must not blur the distinction between mechanistic promise and proven fracture reduction.

This distinction has practical implications for future trial eligibility. Women already receiving bisphosphonates, denosumab, anabolic agents, or menopausal hormone therapy should either be excluded from early efficacy trials or analyzed in predefined strata, because these treatments can strongly alter Bone-Turnover Markers and BMD. Alternatively, an adjunctive design could deliberately examine whether palm TRF adds metabolic or muscle benefits to stable standard therapy, but this would answer a different research question.

Safety and interaction monitoring are also essential. Palm TRF has been evaluated across multiple randomized trials and broader reviews without a signal that would justify assuming unusual toxicity, but the safety profile of long-duration, high-dose supplementation in older women with polypharmacy still requires active surveillance [11-35].

Research Roadmap for Palm-Derived Tocotrienols

A staged research strategy is preferable to a single definitive trial attempted too early. Phase 1 should establish formulation chemistry and pharmacokinetics. Investigators should report the exact α-, β-, γ-, and δ-tocotrienol content, tocopherol content, excipients, delivery system and batch stability. Plasma concentration–time profiles should determine whether the intended isoforms achieve meaningful exposure and whether coexisting α-tocopherol modifies that exposure.

Phase 2 should focus on mechanism-rich short studies lasting approximately three to six months. Outcomes should include CTX, P1NP, oxidative-stress markers, inflammatory mediators, lipidomics, targeted acylcarnitines, tryptophan-related metabolites, and steroid-related metabolites. These trials should be large enough to compare palm TRF with annatto δ/γ preparations and should stratify or adjust for vitamin D status, calcium intake, BMI, insulin resistance, and years since menopause.

Phase 3 should shift toward structural and functional outcomes over 12–24 months. DXA at the lumbar spine, femoral neck and total hip should remain standard, but trabecular bone score and HR-pQCT could reveal changes that conventional areal BMD misses. Fracture endpoints would require substantially larger and longer studies. Muscle outcomes should be incorporated to determine whether metabolic effects translate into improved strength, performance, or fall-related risk.

This proposed sequence is summarized in Figure 4, which converts the review's evidence gaps into a translational research program. The roadmap also identifies vitamin D status, calcium intake, adiposity, diabetes or insulin resistance, menopausal duration, and concurrent osteoporosis therapy as cross-cutting modifiers that should be addressed at every stage.




Figure 4: Research Roadmap for Palm-Derived Tocotrienols in Postmenopausal Bone Health

Figure 4 highlights that the translational problem cannot be solved by simply repeating short biomarker trials. The research sequence must establish exposure, verify mechanism, demonstrate structural skeletal relevance, and only then examine fracture or implementation outcomes. This approach would also allow the palm sector to build evidence that is genuinely product- and source-specific rather than dependent on extrapolation from annatto research

Strengths and Limitations of the Review

A major strength of this review is its source-specific analytical framework, which separates palm-derived TRF from annatto-dominant and other tocotrienol preparations instead of treating tocotrienols as a homogeneous exposure. The review also integrates skeletal biology with redox regulation, lipid metabolism, marrow adiposity, insulin resistance, metabolomics, and muscle-bone communication, thereby providing a broader translational framework than a mechanism-by-mechanism summary.

The review also has limitations inherent to a qualitative literature synthesis. It was designed for thematic integration rather than exhaustive study capture, formal risk-of-bias scoring, or quantitative effect-size pooling, and several mechanistic pathways are supported mainly

by preclinical evidence. In addition, heterogeneous tocotrienol formulations, doses, delivery systems, populations, and outcome definitions limit cross-study comparability; consequently, causal and formulation-specific clinical conclusions are intentionally conservative.

Conclusion

Postmenopausal bone loss is best understood as the product of an interconnected endocrine–redox–inflammatory–metabolic network. Estrogen deficiency initiates remodeling imbalance, but oxidative stress, inflammation, mitochondrial dysfunction, lipid remodeling, marrow adiposity, insulin resistance, and muscle deterioration influence the magnitude and clinical consequences of skeletal decline. This broader model provides a strong biological rationale for studying tocotrienols because their reported actions intersect several of these pathways.

The available evidence nevertheless requires cautious interpretation. Human studies demonstrate that tocotrienol supplementation can generate measurable changes in bone-related biomarkers and systemic metabolic profiles, and metabolomics has revealed changes in lysophospholipids, acylcarnitines, tryptophan-related metabolites, and steroid-associated pathways. These observations support biological activity but do not establish long-term preservation of BMD, bone microarchitecture, or fracture reduction.

The most important conclusion is methodological: tocotrienols are not a single interchangeable intervention. Palm-derived TRF and annatto-dominant δ/γ preparations differ in source, isoform composition, tocopherol content, delivery characteristics, and pharmacokinetics. Evidence generated with one formulation should therefore inform hypotheses about another formulation but should not be treated as direct proof of equivalent skeletal efficacy.

Future research should prioritize well-characterized palm-specific formulations, head-to-head isoform comparisons, pharmacokinetic assessment, longer randomized trials, DXA and advanced imaging, bone-turnover markers, oxidative and inflammatory biomarkers, metabolomics and combined bone–muscle outcomes. Vitamin-D status, calcium intake, obesity, insulin resistance, diabetes, years since menopause and concurrent osteoporosis treatment should be incorporated as predefined modifiers. Until such evidence is available, palm-derived tocotrienols are most appropriately regarded as a promising formulation-specific research candidate and potential adjunct to established bone-health strategies, rather than a proven treatment for postmenopausal osteoporosis.

References

1. Mohamad NV, Ima Nirwana S, Chin KY (2020) Are oxidative stress and inflammation mediators of bone loss due to estrogen deficiency A review of current evidence. Endocrine Metabolic & Immune Disorders Drug Targets 20: 1478-1487.
2. Cheng CH, Chen LR, Chen KH (2022) Osteoporosis due to hormone imbalance An overview of the effects of estrogen deficiency and glucocorticoid overuse on bone turnover. International Journal of Molecular Sciences 23: 1376.
3. Polyzos SA, Anastasilakis AD, Efstathiadou ZA, Yavropoulou MP, Makras P, et al. (2021) Postmenopausal osteoporosis coexisting with other metabolic diseases Treatment considerations. Maturitas 147: 19-25.
4. Yasuda H (2021) Discovery of the RANKL/RANK/OPG system. Journal of Bone and Mineral Metabolism 39: 2-11.
5. Liu J, Qing Xiao, Jiani Xiao, Chenxi Niu, Yuanyuan Li, et al. (2022) Wnt/β-catenin signalling Function, biological mechanisms, and therapeutic opportunities. Signal Transduction and Targeted Therapy 7: 3.
6. Zhao F, Guo L, Wang X, Zhang Y (2021) Correlation of oxidative stress-related biomarkers with postmenopausal osteoporosis A systematic review and meta-analysis. Archives of Osteoporosis 16: 4.
7. Khor BH, Hui Ci Tiong, Shing Cheng Tan, Sok Kuan Wong, Kok Yong Chin
8. et al. (2021) Effects of tocotrienols supplementation on markers of inflammation and oxidative stress A systematic review and meta-analysis of randomized controlled trials. PLoS ONE 16: e0255205.
9. Lavhale MP, Mandlik SK, Shinde VM, Mandlik DS (2025) Nrf2 signaling in bone health Unlocking new avenues for osteoporosis management. Inflammopharmacology 33: 6419-6455.
10. Wong SK, Yusof Kamisah, Norazlina Mohamed, Norliza Muhammad, Norliana Masbah, et al. (2020) Potential role of tocotrienols on non-communicable diseases A review of current evidence. Nutrients 12: 259.
11. Zainal Z, Khaza ai H, Radhakrishnan AK, Chang SK (2022) Therapeutic potential of palm oil vitamin E-derived tocotrienols in inflammation and chronic diseases Evidence from preclinical and clinical studies. Food Research International 156: 111175.
12. Looi AD, Palanisamy UD, Moorthy M, Radhakrishnan AK (2025) Health benefits of palm tocotrienol-rich fraction A systematic review of randomized controlled trials. Nutrition Reviews 83: 307-328.
13. Sharif M, Khan DA, Farhat K, Noor M, Khan MA, et al. (2023) Pharmacokinetics and bioavailability of tocotrienols in healthy human volunteers A systematic review. Journal of the Pakistan Medical Association 73: 603-610.
14. Liang G, Kow ASF, Tham CL, Ho YC, Lee MT, et al. (2022) Ameliorative effect of tocotrienols on perimenopausal-associated osteoporosis-A review. Antioxidants 11: 2179.
15. Saud Gany SL, Chin KY, Tan JK, Aminuddin A, Makpol S, et al. (2023) Preventative and therapeutic potential of tocotrienols on musculoskeletal diseases in ageing. Frontiers in Pharmacology 14: 1290721.
16. Looi AD, Palanisamy UD, Moorthy M, Radhakrishnan AK (2025) Health benefits of palm tocotrienol-rich fraction A systematic review of randomized controlled trials. Nutrition Reviews 83: 307-328.
17. Camacho PM, Steven M Petak, Neil Binkley, Michael McClung, Sunil J Wimalawansa, et al. (2020) American Association of Clinical Endocrinologists/American College of Endocrinology clinical practice guidelines for the diagnosis and treatment of postmenopausal osteoporosis-2020 update. Endocrine Practice, 26: 1-46.
18. Gregson CL, David J Armstrong, Jean Bowden, Cyrus Cooper, John Edwards, et al. (2022) UK clinical guideline for the prevention and treatment of osteoporosis. Archives of Osteoporosis 17: 58.
19. Liu J, Gao Z, Liu X (2024) Mitochondrial dysfunction and therapeutic perspectives in osteoporosis. Frontiers in Endocrinology 15:1325317.
20. Li GF, Gao Y, Weinberg ED, Huang X, Xu YJ, et al. (2023) Role of iron accumulation in osteoporosis and the underlying mechanisms Current Medical Science, 43: 647-654.
21. Wu X, Xiaoxin Fang, Feng Lu, Qiong Chen, Junjian Liu, et al. (2024) An update on the role of ferroptosis in the pathogenesis of osteoporosis. EFORT Open Reviews 9: 712-722.

22. Rendina Ruedy E, Rosen CJ (2020) Lipids in the bone marrow An evolving perspective. Cell Metabolism 31: 219-231.
23. Li J, Chen X, Lu L, Yu X (2020) The relationship between bone marrow adipose tissue and bone metabolism in postmenopausal osteoporosis. Cytokine & Growth Factor Reviews 52: 88-98.
24. Milišić L, Vegar Zubović S, Valjevac A (2020) Bone marrow adiposity is inversely associated with bone mineral density in postmenopausal females. Medical Glasnik, 17: 15-21.
25. Zhang X, Tian L, Majumdar A, Scheller EL (2024) Function and regulation of bone marrow adipose tissue in health and disease State of the field and clinical considerations. Comprehensive Physiology 14:5521-5579.
26. Niu H, Zhou M, Xu X, Xu X (2024) Bone marrow adipose tissue as a critical regulator of postmenopausal osteoporosis-A concise review. Clinical Interventions in Aging 19: 1259-1272.
27. Rosen CJ, Horowitz MC (2023) Nutrient regulation of bone marrow adipose tissue Skeletal implications of weight loss. Nature Reviews Endocrinology 19: 626-638.
28. Shu L, Fu Y, Sun H (2022) The association between common serum adipokines levels and postmenopausal osteoporosis A meta-analysis. Journal of Cellular and Molecular Medicine 26: 4333-4342.
29. Mangion D, Pace NP, Formosa MM (2023) The relationship between adipokine levels and bone mass-A systematic review. Endocrinology, Diabetes & Metabolism 6: e408.
30. Deepika F, Bathina S, Armamento Villareal R (2023) Novel adipokines and their role in bone metabolism A narrative review. Biomedicines 11: 644.
31. Peng H, Biao Hu, Ling Qi Xie1, Yan Huang, Tie Jian Jiang, et al. (2022) A mechanosensitive lipolytic factor in the bone marrow promotes osteogenesis and lymphopoiesis. Cell Metabolism 34: 1168-1182.e6.
32. Zolfaroli I, Ortiz E, García Pérez MÁ, Hidalgo Mora, JJ, Tarín JJ, et al. (2021) Positive association of high-density lipoprotein cholesterol with lumbar and femoral neck bone mineral density in postmenopausal women. Maturitas 147: 41-46.
33. Ye F, Yanlin Zhang, Ziqin Chen, Jing Zhou, Jing Wang, et al. (2025) Serum lipid levels serve as predictors for osteoporosis or osteopenia in postmenopausal women A meta-analysis of observational studies. Drug Discoveries & Therapeutics 19: 220-229.
34. Liu W, Wang C, Hao J, Yin L, Wang Y, et al. (2021) Association between metabolic syndrome and osteoporosis A systematic review and meta-analysis. International Journal of Endocrinology 2021: 6691487.
35. Brandt IAG, Starup Linde J, Andersen SS, Viggers R (2024) Diagnosing osteoporosis in diabetes A systematic review on BMD and fractures. Current Osteoporosis Reports 22: 223-244.
36. Li M, Min Li, Lei Gao, Ying Liu, Yongli Zheng, Luyao Chen, et al. (2025) Relationship between insulin resistance surrogates and bone mineral density in postmenopausal women. Climacteric 28: 154-161.
37. Ismail M, Abdulsamad Alsalahi, Mustapha Umar Imam, Der Jiun Ooi, Huzwah Khaza'ai, et al. (2020) Safety and neuroprotective efficacy of palm oil and tocotrienol-rich fraction from palm oil A systematic review. Nutrients 12: 521.
38. Zuo S, Guiping Wang, QuanLe Han, Hongling Xiao, Heitor O Santos, et al. (2020) The effects of tocotrienol supplementation on lipid profile A meta-analysis of randomized controlled trials. Complementary Therapies in Medicine 52: 102450.
39. Chin KY (2024) Updates in the skeletal and joint protective effects of tocotrienol A mini review. Frontiers in Endocrinology 15: 1417191.
40. Ooi AG, Yuen KH, Chu CC, Wong JW (2026) Oral delivery of tocotrienols Addressing pharmacokinetic challenges with formulation-based strategies. Lipids Advance online publication.
41. Ekeuku SO, Mohd Ramli ES, Abdullah Sani N, Abd Ghafar N, Soelaiman IN, et al. (2022) Tocotrienol as a protecting agent against glucocorticoid-induced osteoporosis A mini review of potential mechanisms. Molecules 27: 5862.
42. Mohamad NV, Soelaiman Ima Nirwana, Kok Yong Chin (2021) Therapeutic potential of annatto tocotrienol with self-emulsifying drug delivery system in a rat model of postmenopausal bone loss. Biomedicine & Pharmacotherapy 137-: 111368.
43. Migliorini F, Nicola Maffulli, Filippo Spiezia, Giuseppe Maria Peretti, Markus Tingart, et al. (2021) Potential of biomarkers during pharmacological therapy setting for postmenopausal osteoporosis A systematic review. Journal of Orthopaedic Surgery and Research 16: 351.
44. Shen CL, Mo H, Dunn DM, Watkins BA (2021) Tocotrienol supplementation led to higher serum levels of lysophospholipids but lower acylcarnitines in postmenopausal women A randomized double-blinded placebo-controlled clinical trial. Frontiers in Nutrition 8: 766711.
45. Yan L, Xianfeng Wang, Tiantian Yu, Zhiming Qi, Huan Li, et al. (2024) Characteristics of the gut microbiota and serum metabolites in postmenopausal women with reduced bone mineral density. Frontiers in Cellular and Infection Microbiology 14: 1367325.
46. Chen C, Zheng Cao, Hehua Lei, Cui Zhang, Mengjing Wu, et al. (2024) Microbial tryptophan metabolites ameliorate ovariectomy-induced bone loss by repairing intestinal AhR-mediated gut-bone signaling pathway. Advanced Science 11: 2404545.
47. Pervez MA, Dilshad Ahmed Khan, Shakeel Ahmed Mirza, Atiq Ur Rehman Slehria, Uzma Nisar, et al. (2022) Comparison of delta-tocotrienol and alpha-tocopherol effects on hepatic steatosis and inflammatory biomarkers in patients with non-alcoholic fatty liver disease: A randomized double-blind active-controlled trial. Complementary Therapies in Medicine 70: 102866.
48. Phang SCW, Ahmad B, Abdul Kadir K, Palanisamy UDM (2023) Effects of tocotrienol-rich fraction supplementation in patients with type 2 diabetes A systematic review and meta-analysis of randomized controlled trials. Advances in Nutrition 14: 1159-1169.
49. Clynes MA, Gregson CL, Bruyère O, Cooper C, Dennison EM, et al. (2021) Osteosarcopenia Where osteoporosis and sarcopenia collide. Rheumatology 60: 529-537.
50. He C, Wenzhen He, Jing Hou, Kaixuan Chen, Mei Huang, et al. (2020) Bone and muscle crosstalk in aging. Frontiers in Cell and Developmental Biology 8: 585644.
51. Yu C, Yongjun Du, Zhi Peng, Chengjie Ma, Junhua Fang, et al. (2023) Research advances in crosstalk between muscle and bone in osteosarcopenia. Experimental and Therapeutic Medicine 25:189.
52. Kaji H (2024) Crosstalk between muscle and bone. Journal of Bone and Mineral Metabolism 42: 391-398.
53. Jang SY, Choi KM (2024) Bidirectional crosstalk between bone and muscle The role of RANKL pathway in osteosarcopenia Journal of Endocrinology 262: e240093.
54. Zhang JL, Poon CCW, Wong MS, Li WX, Guo YX, et al. (2022) Vitamin D supplementation improves handgrip strength in postmenopausal women A systematic review and

meta-analysis of randomized controlled trials. Frontiers in Endocrinology 13: 863448.

55. Shevroja E, Francesco Pio Cafarelli, Giuseppe Guglielmi, Didier Hans, (2021) DXA parameters, Trabecular Bone Score (TBS) and Bone Mineral Density (BMD) in fracture risk prediction in endocrine-mediated secondary osteoporosis. Endocrine 74: 20-28.
56. Liu C, Kuang X, Li K, Guo X, Deng Q, et al. (2020) Effects of combined calcium and vitamin D supplementation on osteoporosis in postmenopausal women A systematic review and meta-analysis of randomized controlled trials. Food & Function 11: 10817-10827.
57. Chakhtoura, M, Dania S Bacha, Charbel Gharios, Sara Ajjour, Mariam Assaad, et al. (2022) Vitamin D supplementation and fractures in adults A systematic umbrella review of meta-analyses of controlled trials. Journal of Clinical Endocrinology & Metabolism 107: 882-898.
58. Panahi N, B Arjmand, A Ostovar, E Kouhestani, R Heshmat, et al. (2021) Metabolomic biomarkers of low BMD A systematic review Osteoporosis International 32: 2407-2431.
59. Liu HF, Meng DF, Yu P, De JC, Li HY, et al. (2023) Obesity and risk of fracture in postmenopausal women A meta-analysis of cohort studies. Annals of Medicine 55: 2203515.

Copyright: ©2026 Loso Judijanto. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.